Improving ADC Research via Surface Proteomics
Antibody-drug conjugates (ADCs) represent a paradigm shift in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs through sophisticated linker chemistry. Despite remarkable clinical successes...
Beyond Protein Levels: Phosphoproteomics for mRNA Therapies
Your ELISA confirms the therapeutic enzyme is present. Your Western blot shows a band at the correct molecular weight. But here’s the critical question: is the enzyme actually functional? For mRNA-based enzyme replacement therapies targeting rare metabolic...
Unbiased Proteomics for Molecular Glue Target Discovery
Phenotypic Screening and Target Deconvolution for Molecular Glue Discovery Molecular glue degraders represent a unique class of therapeutic compounds that modify E3 ligase substrate specificity to induce targeted protein degradation. Unlike PROTACs, which require...